Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).Himisha Beltran, Noura J. Choudhury, Melissa L. Johnson et al.|Journal of Clinical Oncology|2024Cited by 37
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H. Owen, Ishmael Jaiyesimi, Hirva Mamdani et al.|Journal of Clinical Oncology|2022Cited by 32
Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).Himisha Beltran, Noura J. Choudhury, Afshin Dowlati et al.|Journal of Clinical Oncology|2024Cited by 30
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2Dwight H. Owen, Ishmael Jaiyesimi, Navneet Singh et al.|Journal of Clinical Oncology|2022Cited by 26
OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung CancerNoura J. Choudhury, Prantesh Jain, Himisha Beltran et al.|Journal of Thoracic Oncology|2024Cited by 12